Developer docs
API playgroundTry for free, no card

Search company profiles

AIMneXt Co.

Full company profile

uuid00eojn6

Namestring
AIMneXt Co.
Legal namestring
AIMneXt Co.
Websiteurl
aimnext.co.kr
Company typeenum
Private
Founded yearstring
-
Descriptiontext

AIMneXt Co. is a Seoul-based digital therapeutics company developing evidence-based software-based medical interventions. Its first commercial product, Somzz, is a digital therapeutic device for the treatment of insomnia, followed by a pipeline of candidates—Meltz, FreyaX, and additional upcoming products—targeting infertility, panic disorder, and atopic dermatitis. The core technology is a clinical R&D platform that integrates multi-disciplinary expertise: psychiatry specialists, clinical and cognitive psychology experts, data analysts, pharmacists, regulatory affairs professionals, and ICT engineers, producing software interventions designed to comply with FDA digital therapeutics approval guidelines for international market access.

The company's business model is B2B and sales-led, with revenue generated through partnerships with health insurers (subscription/recurring), hospitals (subscription/recurring), and pharmaceutical companies (licensing/royalties). It targets the Korean domestic market initially and is positioning for international expansion via FDA-aligned product development. Distribution runs through institutional partners rather than direct-to-consumer channels, and pricing is not publicly disclosed. On March 23, 2026, AIMneXt entered a four-party strategic MOU with SolDoc, AimMed, and TodakCare to establish a digital therapy-based integrated healthcare service model, indicating an emerging ecosystem-partnership distribution strategy alongside its core insurer/hospital/pharma channels.

Short descriptiontext

AIMneXt Co. is a Seoul-based digital therapeutics company developing evidence-based software interventions, starting with Somzz for insomnia, targeting insurers, hospitals, and pharmaceutical companies as primary B2B partners.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
digital therapeutics, software medical devices, evidence-based healthcare, insomnia treatment software, clinical R&D platform
Industry3 codes
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAK
Women’s Health & Fertility Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Insurer partnerships
TypeSubscription Recurring
Description

Revenue generation through partnerships with health insurance providers for digital therapeutic coverage

aimnext.co.kr:443
2Hospital partnerships
TypeSubscription Recurring
Description

Revenue from hospital partnerships for digital therapeutic solutions

aimnext.co.kr:443
3Pharma partnerships
TypeLicensing Royalties
Description

Revenue through pharmaceutical company partnerships for digital therapeutics integration

aimnext.co.kr:443
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Somzz
Description

Digital therapeutic device for insomnia treatment.

aimnext.co.kr:443
+3 more records
Core offering1 text field

AIMneXt Co. develops and commercializes evidence-based digital therapeutic software products that deliver non-drug, software-based interventions to patients. Its lead product, Somzz, is a digital therapeutic device for insomnia treatment launching in the Korean market, with pipeline candidates Meltz and FreyaX expanding into infertility, panic disorder, and atopic dermatitis. The company targets FDA digital therapeutics approval guidelines to support international market entry.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AIMneXt develops a portfolio of evidence-based digital therapeutic software products for healthcare. The company started with Somzz for insomnia treatment and is expanding into additional therapeutic areas including infertility (난임), panic disorder (공황장애), and atopic dermatitis (아토피). The product portfolio follows FDA digital therapeutics approval guidelines and aims to serve both domestic Korean and international markets. Revenue models are based on partnerships with insurers, hospitals, and pharmaceutical companies.

Product and service3 records
1Somzz
CategoryDigital Therapeutic
Description

Digital therapeutic device for treating insomnia. A non-drug, evidence-based software intervention designed for safe and effective treatment of insomnia patients, intended to be prescribed and administered via healthcare partners.

2Meltz
CategoryDigital Therapeutic Pipeline
Description

Pipeline digital therapeutic candidate included in AIMneXt's portfolio of evidence-based software interventions for disease prevention and treatment.

3FreyaX
CategoryDigital Therapeutic Pipeline
Description

Pipeline digital therapeutic candidate within AIMneXt's portfolio of evidence-based software interventions.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

SolDoc, a non-face-to-face medical treatment solution company, signed a four-party strategic memorandum of understanding with AimNext, AimMed, and TodakCare to establish a digital therapy-based integrated healthcare service model and promote business cooperation among the four parties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Part of the four-party strategic MOU signed to establish a digital therapy-based integrated healthcare service model; AimNext is collaborating with AimMed alongside SolDoc and TodakCare.

3TodakCare
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Part of the four-party strategic MOU signed to establish a digital therapy-based integrated healthcare service model; TodakCare joins SolDoc, AimNext, and AimMed in this collaborative partnership.

startuptoday.kr
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Prescription digital therapeutics developer pursuing FDA software-as-a-medical-device clearances across mental health and chronic conditions, with pharma partnership licensing structures similar to AIMneXt's.

TypeDirect peer
Description

Digital mental health platform offering evidence-based therapeutic software for anxiety and depression, competing with AIMneXt's insomnia and panic disorder indications via insurer and employer channels.

TypeDirect peer
Description

Digital therapeutics company commercializing prescription software-based treatments (e.g., for ADHD and cognitive dysfunction) via FDA-cleared SaMD pathways, closely mirroring AIMneXt's regulatory and commercial approach.

4CureApp
TypeDirect peer
Description

Japan-based digital therapeutics company developing prescription software medical devices, including for nicotine addiction and hypertension, with parallel SaMD regulatory pathway experience in Asia comparable to AIMneXt.

TypeDirect peer
Description

Developer of Sleepio, a digital therapeutic for insomnia. Most directly comparable to AIMneXt's Somzz product, operating in the same FDA-aligned DTx category targeting insurers, hospitals, and employers.

6Pear Therapeutics
TypeDirect peer
Description

Pioneer in prescription digital therapeutics with FDA-cleared products across substance use disorder, insomnia, and other indications, anchoring the DTx commercial and reimbursement model AIMneXt is targeting.

TypeDirect peer
Description

Digital therapeutics company focused on chronic pain and musculoskeletal conditions via evidence-based software interventions, operating a similar B2B partnership model with insurers and employers.

TypeDirect peer
Description

AI-driven conversational digital therapeutic for mental health, sharing AIMneXt's positioning of software-based, evidence-backed interventions that can integrate into care delivery and pharma pipelines.

TypeDirect peer
Description

Developer of digital neurotherapeutics and rehabilitation software, sharing AIMneXt's combination of clinical evidence generation, prescription digital therapeutic positioning, and multi-indication CNS focus.

TypeBroad incumbent
Description

Major Korean digital health platform from the Kakao ecosystem offering telemedicine and digital wellness, providing a broader incumbent benchmark for AIMneXt's Korean market positioning and partnership channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AIMneXt Co.

Digital Therapeuticsaimnext.co.kr

AIMneXt Co. is a Seoul-based digital therapeutics company developing evidence-based software interventions, starting with Somzz for insomnia, targeting insurers, hospitals, and pharmaceutical companies as primary B2B partners.

What AIMneXt Co. does

AIMneXt Co. is a Seoul-based digital therapeutics company developing evidence-based software-based medical interventions. Its first commercial product, Somzz, is a digital therapeutic device for the treatment of insomnia, followed by a pipeline of candidates—Meltz, FreyaX, and additional upcoming products—targeting infertility, panic disorder, and atopic dermatitis. The core technology is a clinical R&D platform that integrates multi-disciplinary expertise: psychiatry specialists, clinical and cognitive psychology experts, data analysts, pharmacists, regulatory affairs professionals, and ICT engineers, producing software interventions designed to comply with FDA digital therapeutics approval guidelines for international market access.

The company's business model is B2B and sales-led, with revenue generated through partnerships with health insurers (subscription/recurring), hospitals (subscription/recurring), and pharmaceutical companies (licensing/royalties). It targets the Korean domestic market initially and is positioning for international expansion via FDA-aligned product development. Distribution runs through institutional partners rather than direct-to-consumer channels, and pricing is not publicly disclosed. On March 23, 2026, AIMneXt entered a four-party strategic MOU with SolDoc, AimMed, and TodakCare to establish a digital therapy-based integrated healthcare service model, indicating an emerging ecosystem-partnership distribution strategy alongside its core insurer/hospital/pharma channels.

AIMneXt Co. firmographics

Firmographics
Name
AIMneXt Co.
Legal name
AIMneXt Co.
Website
https://aimnext.co.kr
Company type
Private
Operating status
Operating
Short description
AIMneXt Co. is a Seoul-based digital therapeutics company developing evidence-based software interventions, starting with Somzz for insomnia, targeting insurers, hospitals, and pharmaceutical companies as primary B2B partners.
Ownership category
akta.pro rank

AIMneXt Co. industry classification

Industry
Product category
Digital Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAK
Women’s Health & Fertility Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital therapeutics
  • Software medical devices
  • Evidence-based healthcare
  • Insomnia treatment software
  • Clinical R&D platform

Where AIMneXt Co. is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Markets served

AIMneXt Co. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Insurer partnerships: Revenue generation through partnerships with health insurance providers for digital therapeutic coverage
  2. Hospital partnerships: Revenue from hospital partnerships for digital therapeutic solutions
  3. Pharma partnerships: Revenue through pharmaceutical company partnerships for digital therapeutics integration

Go-to-market motion1 record

AIMneXt Co. product offering

Product offering

Core offering

AIMneXt Co. develops and commercializes evidence-based digital therapeutic software products that deliver non-drug, software-based interventions to patients. Its lead product, Somzz, is a digital therapeutic device for insomnia treatment launching in the Korean market, with pipeline candidates Meltz and FreyaX expanding into infertility, panic disorder, and atopic dermatitis. The company targets FDA digital therapeutics approval guidelines to support international market entry.

Product overview

AIMneXt develops a portfolio of evidence-based digital therapeutic software products for healthcare. The company started with Somzz for insomnia treatment and is expanding into additional therapeutic areas including infertility (난임), panic disorder (공황장애), and atopic dermatitis (아토피). The product portfolio follows FDA digital therapeutics approval guidelines and aims to serve both domestic Korean and international markets. Revenue models are based on partnerships with insurers, hospitals, and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

  • Somzz: Digital therapeutic device for insomnia treatment.
  • Meltz
  • FreyaX
  • Upcoming

Products and services

  • Somzz Digital therapeutic device for treating insomnia. A non-drug, evidence-based software intervention designed for safe and effective treatment of insomnia patients, intended to be prescribed and administered via healthcare partners.
  • Meltz Pipeline digital therapeutic candidate included in AIMneXt's portfolio of evidence-based software interventions for disease prevention and treatment.
  • FreyaX Pipeline digital therapeutic candidate within AIMneXt's portfolio of evidence-based software interventions.

Companies that use AIMneXt Co.

Customer profile

Segments3 records

Ideal customer profiles3 records

AIMneXt Co. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AIMneXt Co. partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • SolDoccoreStrategic or Co-development Partner · 23 March 2026SolDoc, a non-face-to-face medical treatment solution company, signed a four-party strategic memorandum of understanding with AimNext, AimMed, and TodakCare to establish a digital therapy-based integrated healthcare service model and promote business cooperation among the four parties.
  • AimMedcoreStrategic or Co-development Partner · 23 March 2026Part of the four-party strategic MOU signed to establish a digital therapy-based integrated healthcare service model; AimNext is collaborating with AimMed alongside SolDoc and TodakCare.
  • TodakCarecoreStrategic or Co-development Partner · 23 March 2026Part of the four-party strategic MOU signed to establish a digital therapy-based integrated healthcare service model; TodakCare joins SolDoc, AimNext, and AimMed in this collaborative partnership.

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

AIMneXt Co. competitors and assessment

Company assessment

Direct peers

  • Click Therapeutics: Prescription digital therapeutics developer pursuing FDA software-as-a-medical-device clearances across mental health and chronic conditions, with pharma partnership licensing structures similar to AIMneXt's.
  • Happify Health: Digital mental health platform offering evidence-based therapeutic software for anxiety and depression, competing with AIMneXt's insomnia and panic disorder indications via insurer and employer channels.
  • Akili Interactive: Digital therapeutics company commercializing prescription software-based treatments (e.g., for ADHD and cognitive dysfunction) via FDA-cleared SaMD pathways, closely mirroring AIMneXt's regulatory and commercial approach.
  • CureApp: Japan-based digital therapeutics company developing prescription software medical devices, including for nicotine addiction and hypertension, with parallel SaMD regulatory pathway experience in Asia comparable to AIMneXt.
  • Big Health: Developer of Sleepio, a digital therapeutic for insomnia. Most directly comparable to AIMneXt's Somzz product, operating in the same FDA-aligned DTx category targeting insurers, hospitals, and employers.
  • Pear Therapeutics: Pioneer in prescription digital therapeutics with FDA-cleared products across substance use disorder, insomnia, and other indications, anchoring the DTx commercial and reimbursement model AIMneXt is targeting.
  • Kaia Health: Digital therapeutics company focused on chronic pain and musculoskeletal conditions via evidence-based software interventions, operating a similar B2B partnership model with insurers and employers.
  • Woebot Health: AI-driven conversational digital therapeutic for mental health, sharing AIMneXt's positioning of software-based, evidence-backed interventions that can integrate into care delivery and pharma pipelines.
  • MindMaze: Developer of digital neurotherapeutics and rehabilitation software, sharing AIMneXt's combination of clinical evidence generation, prescription digital therapeutic positioning, and multi-indication CNS focus.

Broad incumbents

  • Kakao Healthcare: Major Korean digital health platform from the Kakao ecosystem offering telemedicine and digital wellness, providing a broader incumbent benchmark for AIMneXt's Korean market positioning and partnership channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

AIMneXt Co. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AIMneXt Co. leadership team

Management profile

Number of profiles

AIMneXt Co. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AIMneXt Co. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIMneXt Co.

What does AIMneXt Co. do?

AIMneXt Co. develops and commercializes evidence-based digital therapeutic software products that deliver non-drug, software-based interventions to patients. Its lead product, Somzz, is a digital therapeutic device for insomnia treatment launching in the Korean market, with pipeline candidates Meltz and FreyaX expanding into infertility, panic disorder, and atopic dermatitis. The company targets FDA digital therapeutics approval guidelines to support international market entry.

Is AIMneXt Co. a public or private company?

AIMneXt Co. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AIMneXt Co. founded?

AIMneXt Co. was founded in -1.

Where is AIMneXt Co. based?

AIMneXt Co. is headquartered in Seoul, South Korea, in the Asia region.

How does AIMneXt Co. make money?

Three revenue lines are on record. Insurer partnerships are the primary driver. The others are hospital partnerships and pharma partnerships.

Who are AIMneXt Co.'s main competitors?

Direct peers on record are Click Therapeutics, Happify Health, Akili Interactive, CureApp, Big Health, Pear Therapeutics, Kaia Health, Woebot Health and MindMaze. Kakao Healthcare is listed as a broad incumbent.

Does AIMneXt Co. have an API?

No public API is recorded for AIMneXt Co..

What industry is AIMneXt Co. in?

AIMneXt Co.'s product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination), with a secondary code of HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales